Trial intelligence / Profile preview

Neoadjuvant XELOX plus surgery versus surgery alone for high-risk resectable colorectal liver metastases

NL-OMON44796Not yet recruiting

Sponsor
Erasmus MC Cancer Institute
Start
Oct 2014
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Trial of capecitabine and oxaliplatin, sponsored by Erasmus MC Cancer Institute. Planned start Oct 2014; status: not yet recruiting.

02

Drugs

capecitabineoxaliplatin

Beyond the preview

Go deeper on NL-OMON44796.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON44796.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call